Condition: Hypertension · MTHFR 677 TT Genotype · Sponsor: Shenzhen Ausa Pharmed Co.,Ltd
This is a multi-center, randomized, double-blind, triple-dummy, controlled trial in 24,000 Chinese men and women with hypertension and MTHFR 677 TT genotype. The study participants will be randomized to one of the three treatment groups: Group A: amlodipine tablet (5mg), taken orally, once daily, serving as active comparator. Group B: amlodipine folic acid 5.8mg tablet (5mg amlodipine and 0.8mg folic acid), taken orally, once daily. Group C: amlodipine folic acid 5.8mg tablet plus 5-methyltetrahydrofolate (5-MTHF, 0.4mg), taken orally, once daily. The primary endpoint is first ischemic stroke.
This description comes directly from the study's public registry record.
Minqing Tian, PhD · 86-18818680849 · tianminqing@163.com
Always discuss trial participation with your own doctor first.
| First Affillated Hospital of Bengbu Medical University | Bengbu, Anhui, China | Not Yet Recruiting |
| Bozhou People's Hospital | Bozhou, Anhui, China | Not Yet Recruiting |
| Chizhou People's Hospital | Chizhou, Anhui, China | Not Yet Recruiting |
| Taihe County People's Hospital | Fuyang, Anhui, China | Not Yet Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Yangjiang People's Hospital | Yangjiang, Guangdong, China | Not Yet Recruiting |
| The Affiliated Hospital of Guizhou Medical University | Guiyang, Guizhou, China | Not Yet Recruiting |
| The First Affiliated Hospital of Hunan University of Medicine | Huaihua, Hunan, China | Not Yet Recruiting |
| Loudi Central Hospital | Loudi, Hunan, China | Not Yet Recruiting |
| Lianyungang Oriental Hospital | Lianyungang, Jiangsu, China | Recruiting |
| The First People's Hospital of Lianyungang | Lianyungang, Jiangsu, China | Not Yet Recruiting |
| The Second People's Hospital of Lianyungang | Lianyungang, Jiangsu, China | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04974151